Puma Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Puma Biotechnology has a total shareholder equity of $51.0M and total debt of $100.0M, which brings its debt-to-equity ratio to 196.2%. Its total assets and total liabilities are $214.1M and $163.2M respectively. Puma Biotechnology's EBIT is $26.6M making its interest coverage ratio 2.6. It has cash and short-term investments of $107.2M.
Key information
196.2%
Debt to equity ratio
US$100.02m
Debt
Interest coverage ratio | 2.6x |
Cash | US$107.16m |
Equity | US$50.98m |
Total liabilities | US$163.17m |
Total assets | US$214.15m |
Recent financial health updates
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Recent updates
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Puma Bio: Still Worthy Of Consideration After Earnings Surprise
Mar 08Financial Position Analysis
Short Term Liabilities: PBYI's short term assets ($143.0M) exceed its short term liabilities ($98.2M).
Long Term Liabilities: PBYI's short term assets ($143.0M) exceed its long term liabilities ($65.0M).
Debt to Equity History and Analysis
Debt Level: PBYI has more cash than its total debt.
Reducing Debt: PBYI's debt to equity ratio has reduced from 351.6% to 196.2% over the past 5 years.
Debt Coverage: PBYI's debt is well covered by operating cash flow (35.6%).
Interest Coverage: PBYI's interest payments on its debt are not well covered by EBIT (2.6x coverage).